Page last updated: 2024-09-05

sb 203580 and fosbretabulin

sb 203580 has been researched along with fosbretabulin in 1 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies (fosbretabulin)	Trials (fosbretabulin)	Recent Studies (post-2010) (fosbretabulin)
3,489	4	1,137	588	21	310

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Lou, L; Quan, H; Xu, Y	1

Other Studies

1 other study(ies) available for sb 203580 and fosbretabulin

Article	Year
p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4. International journal of cancer, 2008, Apr-15, Volume: 122, Issue:8 Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Fluorescent Antibody Technique; Humans; Imidazoles; Liver Neoplasms; Male; Microtubules; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Pyridines; Stilbenes; Time Factors	2008

Article

Year

p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4.

International journal of cancer, 2008, Apr-15, Volume: 122, Issue:8

Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Fluorescent Antibody Technique; Humans; Imidazoles; Liver Neoplasms; Male; Microtubules; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Pyridines; Stilbenes; Time Factors

2008